GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (MEX:GSK1) » Definitions » Cyclically Adjusted Revenue per Share

GSK (MEX:GSK1) Cyclically Adjusted Revenue per Share : MXN218.70 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is GSK Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

GSK's adjusted revenue per share for the three months ended in Mar. 2025 was MXN48.021. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN218.70 for the trailing ten years ended in Mar. 2025.

During the past 12 months, GSK's average Cyclically Adjusted Revenue Growth Rate was 2.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of GSK was 9.10% per year. The lowest was 0.60% per year. And the median was 4.50% per year.

As of today (2025-05-10), GSK's current stock price is MXN356.95. GSK's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was MXN218.70. GSK's Cyclically Adjusted PS Ratio of today is 1.63.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GSK was 2.50. The lowest was 1.49. And the median was 2.02.


GSK Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for GSK's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Cyclically Adjusted Revenue per Share Chart

GSK Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 191.14 247.46 176.90 236.91

GSK Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 177.15 199.99 202.42 236.91 218.70

Competitive Comparison of GSK's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted PS Ratio falls into.


;
;

GSK Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GSK's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=48.021/135.6000*135.6000
=48.021

Current CPI (Mar. 2025) = 135.6000.

GSK Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 36.905 100.100 49.993
201509 40.700 100.200 55.079
201512 41.001 100.400 55.376
201603 39.045 100.400 52.734
201606 44.142 101.000 59.264
201609 48.865 101.500 65.282
201612 49.238 102.200 65.329
201703 43.627 102.700 57.603
201706 43.334 103.500 56.774
201709 48.070 104.300 62.496
201712 50.570 105.000 65.308
201803 46.322 105.100 59.765
201806 48.127 105.900 61.624
201809 49.743 106.600 63.275
201812 51.076 107.100 64.668
201903 49.165 107.000 62.306
201906 47.615 107.900 59.839
201909 57.246 108.400 71.610
201912 54.329 108.500 67.899
202003 65.816 108.600 82.179
202006 54.810 108.800 68.311
202009 61.361 109.200 76.196
202012 -6.660 109.400 -8.255
202103 52.191 109.700 64.513
202106 40.364 111.400 49.132
202109 46.171 112.400 55.701
202112 47.532 114.700 56.193
202203 46.389 116.500 53.994
202206 33.794 120.500 38.029
202209 43.627 122.300 48.371
202212 42.825 125.300 46.345
202303 37.222 126.800 39.805
202306 37.962 129.400 39.781
202309 42.712 130.100 44.518
202312 41.992 130.500 43.633
202403 37.751 131.600 38.898
202406 44.580 133.000 45.451
202409 50.393 133.500 51.186
202412 51.483 135.100 51.674
202503 48.021 135.600 48.021

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


GSK  (MEX:GSK1) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

GSK's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=356.95/218.70
=1.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GSK was 2.50. The lowest was 1.49. And the median was 2.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


GSK Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of GSK's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (MEX:GSK1) » Definitions » Cyclically Adjusted Revenue per Share
Address
79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

GSK Headlines

No Headlines